Patent · US Active

Tricyclic pyridones and pyrimidones

US11845761B2 · kind B2 · utility

0Cited by
3References
30Claims
0Family size

Assignee

Inventors

Key dates

Filing dateDec 8, 2022
Grant dateDec 19, 2023
Priority date—
Expiry dateDec 8, 2042

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC07D519/00
  • WIPO fieldOrganic fine chemistry
  • WIPO sectorChemistry

Abstract

Compounds with KRAS G12C inhibitory active are disclosed and methods of using the same to treat a cancer comprising a K-Ras G12C mutation.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.